

Asia Bio Innovation Summit (ADC&CGT) unveils in Singapore to spotlight Biopharma Innovations

22 August 2025 | News | By Hithaishi C Bhaskar

Unlocking the potential of antibody-drug conjugates (ADCs) and cell and gene therapies (CGT) therapies to drive oncology breakthroughs



The **Asia Bio Innovation Summit 2025**, held in Singapore, emerged as a landmark event in the biopharmaceutical industry, focusing on the transformative potential of antibody-drug conjugates (ADCs) and cell and gene therapies (CGT).

The summit brought together an impressive lineup of over 30 world-class speakers, 10 exhibitors, and 200 attendees, including representatives from regulatory authorities, major pharmaceutical companies, biotech firms, academia, and CXO-level executives. The event also facilitated collaboration with industry chain partners, addressing industry challenges, accelerating research commercialization, and driving innovation in the biopharmaceutical sector across Asia and beyond.

Over two days, the event delved into the latest advancements and challenges in ADC and CGT development, fostering in-depth discussions and collaborations to harness their full potential. A key highlight of the summit was a keynote presentation by Dr. Mingyu Liu, Senior R&D Scientist at Biosyngen, who addressed the critical bottlenecks and future directions in next-generation tumor-infiltrating lymphocyte (TIL) therapies.

The AsiaBio Innovation Summit 2025 provided a platform for ADC and CGT companies from Asia and around the world to showcase the latest technologies and research results. The event promoted international technical exchanges and business collaboration opportunities, fostering advancements in the biopharmaceutical industry.

Dr. Liu emphasized that while TIL therapy has shown remarkable efficacy in cancers like advanced melanoma and cervical cancer, its success in other solid tumors remains limited. To overcome these challenges, Biosyngen has developed a strategic approach that includes a high-efficiency TIL expansion process capable of utilizing both surgical and biopsy samples while preserving antitumor activity. This innovation addresses the logistical constraints of obtaining surgical samples from late-stage cancer patients and allows for cryopreservation of both tumor samples and final cell products.

Dr. Victor Lietao Li, CEO and Founder of Eximmium Pte. Ltd., delivered a keynote speech at the AsiaBio Innovation Summit 2025 in Singapore, focusing on advancements in ADC and CGT. His presentation, titled "Unlocking Cancer Immunotherapy:

Targeting Intracellular Proteins," highlighted the limitations of conventional immunotherapy, which targets cell membrane proteins and faces cross-reactivity with normal cells. He discussed how cancers externalize intracellular proteins, creating specific, oncogenic targets, and shared insights from advanced research and early clinical trials that demonstrate the promise of this approach in cancer immunotherapy.

Additionally, Biosyngen has enhanced the memory T cell populations in their TIL products, achieving an eightfold increase in central memory T cells (TCM) while maintaining optimal CD8+ T cell ratios, critical for long-term therapeutic effects. The company also employs a lentiviral transfection system for stable genetic modification of TILs, achieving a transduction efficiency exceeding 50% and improving their persistence and antitumor activity in vivo.

Xichang Biopharmaceuticals, a leader in the ADC and CGT fields, engaged in discussions with global peers on technological breakthroughs and industry trends, using the platform to exchange ideas and deepen understanding of cutting edge concepts.

Furthermore, Biosyngen's use of specific biomarkers and selective expansion techniques enriches antigen-specific T cells, which has the potential to significantly improve clinical response rates. The summit also highlighted the growing momentum of Asia's biopharma innovation ecosystem. Following the Singapore event, subsequent editions in Chengdu and Shenzhen will focus on regional biopharma policies, innovation ecosystem development, and collaborations between industry and academia.

Experts widely agree that ADC and CGT technologies will play a pivotal role in driving oncology innovation over the next decade. With its dynamic R&D landscape, vast market potential, and strong policy support, Asia is rapidly positioning itself as a global leader in biopharmaceutical breakthroughs.

By facilitating cross-border knowledge exchange and sharing cutting-edge technologies, the Asia Bio Innovation Summit has not only strengthened global collaboration but also accelerated the development of Asia's biopharma industry.

This event injected fresh momentum into the region's efforts to leapfrog in biopharmaceutical innovation, solidifying its role as a critical hub for advancing next-generation therapies.